Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 55

Using fat-derived stem cells to treat primary progressive multiple sclerosis

Official title: Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis: an Open-label Phase I Clinical Trial.

Run by Rennes University Hospital · NCT06592703 · Data updated 2026-11-12

This study is testing if injections of fat-derived stem cells can help people with primary progressive multiple sclerosis feel better and slow down their disease.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment10 (estimated)
SponsorRennes University Hospital
Academic / other
Locations2 sites (Créteil and 1 other locations)
StatusRecruiting
StartedMarch 6, 2025
Main results expectedDecember 2029
Study endsDecember 2029
Registry record updatedJanuary 5, 2026
Trial IDNCT06592703 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 to 55 with a confirmed diagnosis of primary progressive multiple sclerosis and specific disability criteria.

Probably not a fit

Patients with recent inflammatory activity or those currently on disease-modifying drugs may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the safety and potential effectiveness of repeated injections of allogenic adipose tissue-derived mesenchymal stromal cells (ASCs) in patients with primary progressive multiple sclerosis (PPMS). The approach involves administering three intrathecal injections of ASCs every three months, with the hypothesis that this treatment can slow disease progression. The study will begin by establishing a bank of ASCs from healthy donors, followed by screening and enrolling eligible PPMS patients at Rennes University Hospital. Participants will be monitored for one year after receiving the injections.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option to slow the progression of primary progressive multiple sclerosis.

How similar studies have gone: While autologous stem cell therapies have been explored in multiple sclerosis, the use of allogenic adipose-derived stem cells in this context is novel and has not been previously tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017)
* Age between 18 and 55 years
* EDSS score: 3 to 6 at inclusion
* Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit
* Positive CSF with oligoclonal bands
* For women of childbearing potential (WOCBP), effective contraception as per the CFTG recommendations (version 1.1)
* Having signed a free, informed and written consent
* Affiliated to social security scheme

Exclusion Criteria:

* Inflammatory activity during the past year (relapses or new T2 MRI lesions)
* Disease Modifying Drugs during the past year
* Treatment with high dose corticosteroids during the 30 days preceding the inclusion
* Contra indication to lumbar puncture/intrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (\<50 G/L), anticoagulant or fibrinolytic treatment
* Participation in another therapeutic trial in the last 6 months
* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breastfeeding women, minors, persons unable to express their consent

Where it's running

  • CHU Rennes
    Rennes, France
    Recruiting
  • APHP Henri Mondor
    Créteil, France
    Active not recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.